BIO-key Q1 revenue up 34% to $2.15M, net loss narrows to $(165K); sees Q2 profitability on 65% revenue jump

BIO KEY INTERNATIONAL INC

Q1 2026 revenue $2.15M (+34% YoY); net loss improved to $(165K) from $(737K) in Q1 2025.
Gross margin 82%; cash $2.24M at quarter end; EPS $(0.15) post-reverse split.
Q2 2026 revenue guided ~$2.8M (+65% YoY); expects H1 2026 profitability vs H1 2025 net loss of $(1.9M).
Secured $1.04M license renewal with foreign bank; defense sales surpassed $2M in trailing twelve months.
Shares suspended from Nasdaq, now trading OTC under BKYI; company working to return to Nasdaq.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.